Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years
Authors not listed
Beijing BeneWill Technology Development Co., Ltd · 2026
Abstract
This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) in individuals aged 60 and above.
Sample Size and Trial Grouping: This trial plans to enroll 25,000 trial participants aged ≥60 years (with approximately 30% aged 70 and above), with a relatively balanced gender distribution. Participants of each age group (60-69 years old, ≥70 years old) will be randomly assigned to the trial group and the placebo group in a 1:1 ratio. The sample size for the immunogenicity subgroup is not calculated based on statistical power. Referring to similar clinical trials of RSV vaccines and in conjunction with the immunogenicity observation objectives of this trial, the first 300 trial participants (including those from both age groups) from each site under the leading institution will be included in the immunogenicity subgroup, for a total of 1,200 participants.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2026). Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years. <em>Beijing BeneWill Technology Development Co., Ltd</em>. https://clinicaltrials.gov/study/NCT07860216
Vancouver
Anonymous. Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years. Beijing BeneWill Technology Development Co., Ltd. 2026.
BibTeX
@misc{anon2026PhaseI,
title = {Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years},
author = {Anonymous},
journal = {Beijing BeneWill Technology Development Co., Ltd},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Yikang Biotech (Suzhou) Co., Ltd. 2026
Open access · US-GOV
A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Jiangsu Rec-Biotechnology Co., Ltd. 2022
Open access · US-GOV
A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
MAXVAX Biotechnology Limited Liability Company 2024
Open access · US-GOV
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
National Vaccine and Serum Institute, China 2021
Open access · US-GOV
Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older
Guangzhou Patronus Biotech Co., Ltd. 2022
Open access · US-GOV
A Randomized, Blinded, Positive-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above
Guangzhou Patronus Biotech Co., Ltd. 2023
Open access · US-GOV